Suppr超能文献

异基因造血干细胞移植后 24 个月晚期并发症的结局和危险因素。

Outcome and risk factors for late-onset complications 24 months beyond allogeneic hematopoietic stem cell transplantation.

机构信息

Division of Radiation Oncology, University Hospital, Geneva, Switzerland.

出版信息

Eur J Haematol. 2011 Aug;87(2):138-47. doi: 10.1111/j.1600-0609.2011.01638.x.

Abstract

OBJECTIVES

The aim of this retrospective study was to assess the incidence of late complications occurring ≥2 years after allogeneic hematopoietic stem cell transplantation (HSCT) for malignant diseases using a T-cell depletion strategy.

METHODS

Between 1984 and 2004, 142 patients were eligible for the study. Total body irradiation (TBI) was carried out in 85% of the patients and T-cell depletion in 84%.

RESULTS

Non-relapse mortality (NRM) was 3% (95% CI 0-11) at 10 years, and serious late events affected a substantial number of patients. The cumulative incidence (CI) of chronic graft-versus-host disease (cGvHD) was 30% (95% CI 23-40), and that of infectious complications was 17% (95% CI 11-23). Multivariate analysis showed a higher risk for late complications in patients with cGvHD (HR 1.9, 95% CI 1.2-3.2, P=0.011) and patients receiving methylprednisolone during conditioning (HR 1.9, 95% CI 1.1-3.3, P=0.019 1), patients with cGvHD also having a higher risk for NRM (HR 13.2, 95% CI 1.2-143, P=0.03), as well as those receiving steroids for >3 months (HR 40.3, 95% CI 2.3-718, P=0.02) and those receiving antithymocyte globulin (HR 9.6, 95% CI 0.8-68, P=0.024).

CONCLUSIONS

A significant proportion of long-term survivors of HSCT had late complications. cGvHD remained an important risk factor for late complications despite T-cell depletion resulting in immunosuppression and infectious complications.

摘要

目的

本回顾性研究旨在评估采用 T 细胞耗竭策略进行异基因造血干细胞移植(HSCT)治疗恶性疾病后≥2 年发生的迟发性并发症的发生率。

方法

1984 年至 2004 年,142 例患者符合研究条件。85%的患者接受全身照射(TBI),84%的患者接受 T 细胞耗竭。

结果

10 年时非复发死亡率(NRM)为 3%(95%CI 0-11),严重的迟发性事件影响了大量患者。慢性移植物抗宿主病(cGvHD)的累积发生率(CI)为 30%(95%CI 23-40),感染并发症的发生率为 17%(95%CI 11-23)。多变量分析显示,cGvHD 患者(HR 1.9,95%CI 1.2-3.2,P=0.011)和接受甲基强的松龙预处理的患者(HR 1.9,95%CI 1.1-3.3,P=0.019)发生迟发性并发症的风险更高,cGvHD 患者的 NRM 风险也更高(HR 13.2,95%CI 1.2-143,P=0.03),接受皮质类固醇治疗>3 个月的患者(HR 40.3,95%CI 2.3-718,P=0.02)和接受抗胸腺细胞球蛋白治疗的患者(HR 9.6,95%CI 0.8-68,P=0.024)。

结论

尽管 T 细胞耗竭导致免疫抑制和感染并发症,但 HSCT 后相当一部分长期幸存者仍存在迟发性并发症。cGvHD 仍然是迟发性并发症的重要危险因素。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验